Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Shiramoto M, Eto T, Irie S, Fukuzaki A, Teichert L, Tillner J, Takahashi Y, Koyama M, Dahmen R, Heise T, Becker RH. Shiramoto M, et al. Among authors: teichert l. Diabetes Obes Metab. 2015 Mar;17(3):254-60. doi: 10.1111/dom.12415. Epub 2014 Dec 22. Diabetes Obes Metab. 2015. PMID: 25425297 Free PMC article. Clinical Trial.
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, Einig C, Keil S, Haack T, Wagner M, Bossart M, Larsen PJ. Tillner J, et al. Among authors: teichert l. Diabetes Obes Metab. 2019 Jan;21(1):120-128. doi: 10.1111/dom.13494. Epub 2018 Sep 16. Diabetes Obes Metab. 2019. PMID: 30091218 Clinical Trial.
A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.
Kapitza C, Nosek L, Schmider W, Teichert L, Mukherjee B, Nowotny I. Kapitza C, et al. Among authors: teichert l. Diabetes Obes Metab. 2021 Mar;23(3):674-681. doi: 10.1111/dom.14260. Epub 2020 Dec 10. Diabetes Obes Metab. 2021. PMID: 33236518 Free PMC article. Clinical Trial.
Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
Kapitza C, Nosek L, Schmider W, Teichert L, Nowotny I. Kapitza C, et al. Among authors: teichert l. Diabetes Technol Ther. 2020 Apr;22(4):278-284. doi: 10.1089/dia.2019.0351. Epub 2019 Dec 30. Diabetes Technol Ther. 2020. PMID: 31825248 Free PMC article. Clinical Trial.
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS. Shah VN, et al. Among authors: teichert l. Diabetes Obes Metab. 2024 Feb;26(2):540-547. doi: 10.1111/dom.15341. Epub 2023 Oct 25. Diabetes Obes Metab. 2024. PMID: 37880868 Clinical Trial.
Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance.
Kannt A, Pfenninger A, Teichert L, Tönjes A, Dietrich A, Schön MR, Klöting N, Blüher M. Kannt A, et al. Among authors: teichert l. Diabetologia. 2015 Apr;58(4):799-808. doi: 10.1007/s00125-014-3490-7. Epub 2015 Jan 18. Diabetologia. 2015. PMID: 25596852 Free PMC article. Clinical Trial.
14 results